Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lisinopril Clear all
Completed Not applicable Interventional Results available

Cardiovascular Prevention for Persons With HIV

NCT00982189
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease Risk
Interventions
Pravastatin, Lisinopril
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
40 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

NCT01491919
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril
Drug
Lead sponsor
Uptal Patel
Other
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

NCT00874432
View directory record Official record
Conditions
Cardiovascular Disease, Chronic Kidney Disease
Interventions
angiotensin converting enzyme inhibitor, lisinopril
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 3, 2026, 10:13 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100
View directory record Official record
Conditions
Stage 2 Diastolic Hypertension
Interventions
nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
89
States / cities
Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Sep 3, 2026, 10:13 PM EDT
Withdrawn Phase 4 Interventional

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

NCT00994253
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 3, 2026, 10:13 PM EDT
Terminated Phase 3 Interventional

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

NCT00123903
View directory record Official record
Conditions
Heart Failure, Congestive and Microalbuminuria
Interventions
metoprolol xl, carvedilol MR, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 3, 2026, 10:13 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

NCT01009918
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 3, 2026, 10:13 PM EDT
Withdrawn Not applicable Interventional

Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

NCT01076140
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Lisinopril
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00557128
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 2Phase 3 Interventional

Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

NCT01126697
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Coenzyme Q10 and Lisinopril
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 3, 2026, 10:13 PM EDT
Terminated Phase 2 Interventional Results available

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

NCT01234922
View directory record Official record
Conditions
Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

NCT02641899
View directory record Official record
Conditions
Healthy
Interventions
ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin, Lisinopril, Warfarin, Digoxin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

NCT00171535
View directory record Official record
Conditions
Hypertension
Interventions
valsartan/amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 3, 2026, 10:13 PM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Metoprolol, Lisinopril, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

NCT00553969
View directory record Official record
Conditions
Pre-hypertension
Interventions
carvedilol phosphate, lisinopril, carvedilol phosphate and lisinopril, placebo and placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
19 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 3, 2026, 10:13 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

NCT05644769
View directory record Official record
Conditions
Hypertension
Interventions
Determine the presence of Human sequence Ang-(1-12) on no medication, Human sequence Ang-(1-12) on Lisinopril 40mg every day
Other · Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 3, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

NCT00563901
View directory record Official record
Conditions
Hypertension, Coronary Disease, Cerebrovascular Accident
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
2
States / cities
Minneapolis, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 3, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 3, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Microvascular Disease Exercise Trial

NCT02045459
View directory record Official record
Conditions
Coronary Microvascular Disease
Interventions
Exercise Program
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 3, 2026, 10:13 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 3, 2026, 10:13 PM EDT